Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception

Eduardo R. Butelman, K. O. Mei-Chuan, Katarzyna Sobczyk-Kojiro, Henry I. Mosberg, Barbara Van Bemmel, Gerald Zernig, James H. Woods

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

The binding characteristics of the kappa opioid ligands [3H]U69,593 and [3H]bremazocine, the mu opioid ligand [3H][D-ala2,N-Me- Phe4,glycol5]enkephalin and the delta opioid ligand [3H]p-Cl-[D- pen2,5]enkephalin were studied in rhesus monkey brain membranes in saturation binding experiments and were followed by competition binding experiments with a variety of peptidic and nonpeptidic opioid ligands. The [3H]U69,593 sites appeared to be a subset of kappa opioid receptors (kappa- 1 receptors: K(d), 1.2 nM; B(max), 66 fmol/mg). [3H]Bremazocine (in the presence of mu and delta receptor-masking agents), bound to a larger population of kappa receptors (kappa-all: K(d), 0.39 nM; B(max), 227 fmol/mg), which presumably included the aforementioned kappa-1 sites. Competition binding experiments revealed that the presently defined kappa-1 sites were similar to previously reported sites in other mammalian species, particularly in terms of the higher kappa-1 selectivity observed with arylacetamide (e.g., U50,488) vs. benzomorphan kappa agonists (e.g., ethylketocyclazocine). The kappa-selective antagonist norbinaltorphimine (nor-BNI) displayed a very small (2.3-fold) selectivity for kappa-1 vs. kappa-all sites. This led to the prediction that in rhesus monkeys (n = 3), systemically administered nor-BNI (10 mg/kg s.c.) should have a very moderate degree of antagonist selectivity for the antinociceptive effects of a putative kappa-1-agonist, the arylacetamide U50,488 (0.1-3.2 mg/kg s.c.), vs. those of the benzomorphan kappa agonist ethylketocyclazocine (0.01-056 mg/kg s.c.). This prediction was confirmed in vivo because nor-BNI (10 mg/kg) caused a robust and long lasting (up to 21 days) antagonism of the antinociceptive effects of U50,488 and a small but significant antagonism of ethylketocyclazocine. The arylacetamide congener Cl-977 (enadoline), which displayed an 11-fold kappa-1 vs. kappa-all binding selectivity, was not sensitive to nor-BNI pretreatment. This indicates that the kappa subtype- binding profile of an agonist is not necessarily predictive of its sensitivity to nor-BNI in vivo. Overall, the present results suggest that at least two functional kappa receptor populations may be present in rhesus monkey brain.

Original languageEnglish (US)
Pages (from-to)595-601
Number of pages7
JournalJournal of Pharmacology and Experimental Therapeutics
Volume285
Issue number2
StatePublished - 1998
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception'. Together they form a unique fingerprint.

  • Cite this

    Butelman, E. R., Mei-Chuan, K. O., Sobczyk-Kojiro, K., Mosberg, H. I., Van Bemmel, B., Zernig, G., & Woods, J. H. (1998). Kappa-opioid receptor binding populations in rhesus monkey brain: Relationship to an assay of thermal antinociception. Journal of Pharmacology and Experimental Therapeutics, 285(2), 595-601.